Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea · Delayed Price · Currency is KRW 16,210
+440 (2.79%)
Nov 20, 2025, 3:30 PM KST
Onconic Therapeutics Company Description
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea.
It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields.
JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer.
The company was founded in 2020 and is based in Seoul, South Korea.
Onconic Therapeutics Inc.
| Country | South Korea |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | John Kim |
Contact Details
Address: 12 Teheranro-26-gil Seoul, 06236 South Korea | |
| Phone | 82 2 3454 0780 |
| Website | onconic.co.kr |
Stock Details
| Ticker Symbol | 476060 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7476060009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Kim | Chief Executive Officer |
| Jongkil Shin | Chief Financial Officer |